Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1991
No trial phase data available
No trial data available
No trial data available
No approval data available
- A new market outlook covering 2026-2030 projects continued growth in ADME toxicology testing demand, driven by expansion of the global pharmaceutical industry. - North America was the largest regional market in 2025, while Asia-Pacific is expected to be the fastest-growing region through the forecast period. - European pharmaceutical production reached EUR 390.0 billion ($422.8 billion) in 2023, up from EUR 363.3 billion ($393.9 billion) in 2022, according to EFPIA. - Evotec SE launched the Cyprotex e-Store in October 2023, an e-commerce platform providing online access to its ADME-Tox service portfolio.
- Denovo Biopharma has granted exclusive rights to develop and commercialize DB104 (liafensine) in Taiwan to Chuang Yi Global Asset Management Co., Ltd. - DB104 is a first-in-class triple reuptake inhibitor that targets serotonin, norepinephrine, and dopamine transporters for treatment-resistant depression. - The drug utilizes a novel pharmacogenomic biomarker within the ANK3 gene discovered through AI and whole genome scanning to predict efficacy. - Taiwan currently has no approved antidepressants for treatment-resistant depression, representing a significant unmet medical need in the region.
- Pace Life Sciences successfully completed a Pre-Approval Inspection (PAI) from the FDA at its Lebanon, New Jersey laboratory, confirming high standards for data integrity and quality systems. - The Lebanon facility, acquired from Curia in 2024, specializes in Container Closure Integrity Testing (CCIT), drug delivery physical testing, and package distribution testing for pharmaceutical clients. - The successful inspection demonstrates the company's ability to support pharmaceutical programs from first-in-man studies through FDA approval, reinforcing its position as a trusted CRDMO partner. - This achievement follows favorable FDA inspections in 2024 at Pace's laboratories in Oakdale, Minnesota, and San Germán, Puerto Rico, highlighting the company's commitment to regulatory compliance across its network.
